Cytokine inhibition as a strategy for treating systemic lupus erythematosus

Clinical Immunology

Volumn 148, Issue 3, 2013, Pages 335-343

  Clark, Daniel N ^a   Markham, Jillian L ^a   Sloan, Chad S ^a   Poole, Brian D ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Cytokine Inhibitors; Lupus

Indexed keywords

ABF 13; ADALIMUMAB; AMG 714; ANTIRHEUMATIC AGENT; B N 10; BRODALUMAB; BS 10; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GOLIMUMAB; GSK 1070806; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; IXEKIZUMAB; PLACEBO; R H IL 18BP; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 18BP; RILONACEPT; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB;

ABSENCE; ABSENCE OF SIDE EFFECTS; APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; HUMAN; INFECTION; INFLAMMATORY DISEASE; MACROPHAGE; MYCOSIS; NEUTROPENIA; NONHUMAN; OBESITY; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

CYTOKINE INHIBITORS; LUPUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; INTERLEUKIN-15; INTERLEUKIN-18; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881110807     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.11.001     Document Type: Review

References (107)

1. Linker-Israeli M., et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 1991, 147(1):117-123.
2. Brugos B., et al. Serum and urinary cytokine levels of SLE patients. Pharmazie 2012, 67(5):411-413.
3. Kitani A., et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin. Exp. Immunol. 1992, 88(1):75-83.
4. Lee Y.H., et al. The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 2012, 21(1):60-67.
5. Cash H., et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J. Rheumatol. 2010, 37(1):60-70.
6. Richards H.B., et al. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 1998, 188(5):985-990.
7. Ogata A., Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int. J. Rheumatol. 2012, 2012:946048.
8. Illei G.G., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010, 62(2):542-552.
9. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7(6):429-442.
10. Postal M., Appenzeller S. The role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011, 56(3):537-543.
11. Jacob C.O., McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988, 331(6154):356-358.
12. Brennan D.C., et al. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. 1989, 143(11):3470-3475.
13. Rana A., et al. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012, 21(10):1105-1112.
14. Weckerle C.E., et al. Large scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum. 2012, 64(9):2947-2952.
15. Araki D., et al. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern. Med. 2011, 50(17):1843-1848.
16. Luong J.M., et al. Tumour necrosis factor inhibitor-related lupus: safety of switching agents. Clin. Rheumatol. 2010, 29(5):551-553.
17. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin. Proc. 2009, 84(11):979-984.
18. Verma H.D., et al. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. J. Dig. Dis. 2011, 12(5):379-383.
19. Ye C., et al. Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent. J. Rheumatol. 2011, 38(6):1216. (author reply 1217-8).
20. Palucka A.K., et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(9):3372-3377.
21. Aringer M., Crow M.K. A bridge between interferon-alpha and tumor necrosis factor in lupus. J. Rheumatol. 2008, 35(8):1473-1476.
22. Lopez P., et al. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J. Rheumatol. 2008, 35(8):1559-1566.
23. Arora T., et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009, 45(2):124-131.
24. Bopst M., et al. The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin. Eur. J. Immunol. 1998, 28(12):4130-4137.
25. Botto M., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19(1):56-59.
26. Di Muzio G., et al. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int. J. Immunopathol. Pharmacol. 2011, 24(2):357-366.
27. Williams R.O., et al. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J. Immunol. 2000, 165(12):7240-7245.
28. Zheng L., et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377(6547):348-351.
29. Zhu L.J., Yang X., Yu X.Q. Anti-TNF-alpha therapies in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 2010:465898.
30. Zhu L., et al. Decreased expressions of the TNF-alpha signaling adapters in peripheral blood mononuclear cells (PBMCs) are correlated with disease activity in patients with systemic lupus erythematosus. Clin. Rheumatol. 2007, 26(9):1481-1489.
31. Uppal S.S., Hayat S.J., Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18(8):690-697.
32. Aringer M., et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004, 50(10):3161-3169.
33. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10(3):170-181.
34. Le Buanec H., et al. IFN-alpha and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(47):18995-19000.
35. Moore K.W., et al. Interleukin-10. Annu. Rev. Immunol. 1993, 11:165-190.
36. Kuhn R., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75(2):263-274.
37. Yin Z., et al. IL-10 regulates murine lupus. J. Immunol. 2002, 169(4):2148-2155.
38. Rousset F., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(5):1890-1893.
39. Rousset F., et al. Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Int. Immunol. 1995, 7(8):1243-1253.
40. Koenig K.F., et al. Serum cytokine profile in patients with active lupus nephritis. Cytokine 2012, 60(2):410-416.
41. Su D.L., et al. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J. Biomed. Biotechnol. 2012, 2012:347141.
42. Wang H., et al. The abnormal apoptosis of T cell subsets and possible involvement of IL-10 in systemic lupus erythematosus. Cell. Immunol. 2005, 235(2):117-121.
43. Blenman K.R., et al. IL-10 regulation of lupus in the NZM2410 murine model. Lab. Invest. 2006, 86(11):1136-1148.
44. Ravirajan C.T., et al. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford) 2004, 43(4):442-447.
45. Llorente L., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43(8):1790-1800.
46. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117(14):3720-3732.
47. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
48. Sutton C., et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203(7):1685-1691.
49. Migliorini P., et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur. Cytokine Netw. 2010, 21(4):264-271.
50. Sturfelt G., et al. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br. J. Rheumatol. 1997, 36(12):1283-1289.
51. Brugos B., et al. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum. Immunol. 2010, 71(9):874-877.
52. Parks C.G., et al. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. Ann. Rheum. Dis. 2004, 63(1):91-94.
53. Jacob C.O., et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(15):6256-6261.
54. Voronov E., et al. IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur. Cytokine Netw. 2006, 17(2):109-116.
55. Lukens J.R., Gross J.M., Kanneganti T.D. IL-1 family cytokines trigger sterile inflammatory disease. Front. Immunol. 2012, 3:315.
56. Moosig F., et al. IL-1RA in refractory systemic lupus erythematosus. Lupus 2004, 13(8):605-606.
57. Ostendorf B., et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 2005, 64(4):630-633.
58. Wong C.K., et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9(8):589-593.
59. Doreau A., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 2009, 10(7):778-785.
60. Apostolidis S.A., Crispin J.C., Tsokos G.C. IL-17-producing T cells in lupus nephritis. Lupus 2011, 20(2):120-124.
61. Yang J., et al. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50(8):1366-1372.
62. Yang J., et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009, 60(5):1472-1483.
63. McGeachy M.J., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8(12):1390-1397.
64. Langrish C.L., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201(2):233-240.
65. Crispin J.C., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008, 181(12):8761-8766.
66. Chen X.Q., et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J. Clin. Immunol. 2010, 30(2):221-225.
67. Ambrosi A., Espinosa A., Wahren-Herlenius M. IL-17: A new actor in IFN-driven systemic autoimmune diseases. Eur. J. Immunol. 2012, 42(9):2274-2284.
68. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009, 183(5):3160-3169.
69. Leonardi C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366(13):1190-1199.
70. Genovese M.C., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010, 62(4):929-939.
71. Hueber W. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61(12):1693-1700.
72. Hueber W., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2(52):52ra72.
73. M.C. Genovese, et al., Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study, Ann. Rheum. Dis. (in press), http://dx.doi/10.1136/annrheumdis-2012-201601.
74. Papp K.A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 2012, 366(13):1181-1189.
75. Kyttaris V.C., et al. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. 2010, 184(9):4605-4609.
76. Ryan C., et al. The use of ustekinumab in autoimmune disease. Expert. Opin. Biol. Ther. 2010, 10(4):587-604.
77. De Souza A., et al. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch. Dermatol. 2011, 147(8):896-898.
78. Winchester D., Duffin K.C., Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus 2012, 21(9):1007-1010.
79. Kennedy M.K., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191(5):771-780.
80. Di Sabatino A., et al. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev. 2011, 22(1):19-33.
81. Annunziato F., et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204(8):1849-1861.
82. Stonier S.W., Schluns K.S. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol. Lett. 2010, 127(2):85-92.
83. Baranda L., et al. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44(12):1507-1513.
84. Bo H., et al. Elevated expression of transmembrane IL-15 in immune cells correlates with the development of murine lupus: a potential target for immunotherapy against SLE. Scand. J. Immunol. 2009, 69(2):119-129.
85. Park Y.B., et al. Elevated serum interleukin-15 levels in systemic lupus erythematosus. Yonsei Med. J. 1999, 40(4):343-348.
86. Aringer M., et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40(8):876-881.
87. Robak E., et al. Proinflammatory interferon-gamma-inducing monokines (interleukin-12, interleukin-18, interleukin-15)-serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 2002, 13(3):364-368.
88. Ferrari-Lacraz S., et al. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. 2004, 173(9):5818-5826.
89. Baslund B., et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005, 52(9):2686-2692.
90. Liu X., Bao C., Hu D. Elevated interleukin-18 and skewed Th1:Th2 immune response in lupus nephritis. Rheumatol. Int. 2012, 32(1):223-229.
91. Calvani N., et al. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin. Exp. Immunol. 2004, 138(1):171-178.
92. Dinarello C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 2007, 27(1):98-114.
93. Kahlenberg J.M., et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J. Immunol. 2011, 187(11):6143-6156.
94. Menke J., et al. Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int. 2011, 79(4):452-463.
95. Kim Y.M., et al. Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). J. Immunol. 1998, 161(8):4122-4128.
96. Wildbaum G., et al. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 1998, 161(11):6368-6374.
97. Shimizu C., et al. High circulating levels of interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus. Mod. Rheumatol. 2012, 22(1):73-79.
98. Hu D., et al. Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients. Clin. Rheumatol. 2010, 29(7):717-721.
99. Liang D., et al. Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis. Cell. Mol. Immunol. 2006, 3(4):303-306.
100. Novick D., et al. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J. Autoimmun. 2010, 34(2):121-126.
101. Debets R., et al. IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J. Immunol. 2000, 165(9):4950-4956.
102. Novick D., et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10(1):127-136.
103. Novick D., et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001, 14(6):334-342.
104. Takeda K., et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998, 8(3):383-390.
105. Plater-Zyberk C., et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 2001, 108(12):1825-1832.
106. Smeets R.L., et al. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. 2003, 10(12):1004-1011.
107. Tak P.P., Bacchi M., Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur. J. Drug Metab. Pharmacokinet. 2006, 31(2):109-116.